Eucalyptus Oil (1,8-Cineole)

Also called 1,8-cineole, cineole, cineol, eucalyptol, Eucalyptus globulus oil, eucalypti aetheroleum.

The short answer

From 13 sources

Clinical trials of eucalyptus oil mostly test its main constituent, 1,8-cineole, in 200 mg capsules three times daily. Trials in COPD, asthma, acute bronchitis and sinusitis reported benefits, but all came from one research group and two were funded by the company Cassella-med. It is contraindicated under age 2; swallowed oil can cause drowsiness or seizures in children.

Key facts

What it is
Essential oil from Eucalyptus globulus and related species, rich in 1,8-cineole (eucalyptol)12
Top studied outcome
COPD flare-ups: fewer, shorter and milder exacerbations over 6 winter months in 242 patients (grade B); a 2026 network meta-analysis of 18 mucolytic trials ranked cineole first for fewer flare-ups and fewest side effects211
Who ran the trials
Every cineole RCT cited here shares one co-author; the COPD and bronchitis trials were funded by Cassella-med23456
Children
Contraindicated under 24 months (risk of laryngospasm) and in children with a history of seizures1
Side effects
Heartburn, nausea, abdominal pain and diarrhoea by mouth; contact eczema on skin; allergic reactions1
Overdose
Larger-than-labelled doses can cause vomiting, breathing problems, CNS depression and convulsions; in young children 2 to 3 ml of pure oil can cause drowsiness and 5 ml or more marked loss of consciousness17
Seizures
In 17 children seen with seizures after eucalyptus oil drops in water or milk, fits began a median 20 minutes after the dose; a review of 110 published cases (49 children) found inhalation the most common route, and most recovered without complications89

What it is

Eucalyptus oil is the essential oil of eucalyptus leaves; its main constituent, 1,8-cineole (eucalyptol), is sold in capsules.

How it works

Proposed

1,8-cineole is described by trial authors as mucolytic, bronchodilating and anti-inflammatory; in human monocytes it suppressed arachidonic acid metabolism and cytokine production. These are proposed mechanisms for its airway effects.25

Forms, side by side

3 forms named in our sources. The rest show what our data holds, and say plainly where it holds nothing yet.

Eucalyptus Oil (1,8-Cineole) forms compared

3 forms
Eucalyptus Oil (1,8-Cineole) forms compared: 3 forms by 3 attributes. Empty cells are labelled No data yet, or Not graded in the evidence row.
3 forms1,8-cineole capsules (enteric or gut-soluble)Eucalyptus oil for oral useSteam inhalation, chest rubs and bath additives
Absorption in peopleNo head-to-head human data in our sources.2No head-to-head human data in our sources.1Inhaled or applied to skin.1
GI toleranceAdverse events similar to placebo in the COPD trial; occasional heartburn or rash.26Heartburn, abdominal pain, nausea, vomiting and diarrhoea are listed; caution with inflamed or ulcerated gut.1Contact eczema on skin; keep eyes out of the steam and avoid burns from hot water; not on broken or irritated skin.1
Studied forCOPD, asthma, acute bronchitis and sinusitis (200 mg three times daily)Traditional use for cough with colds (EU monograph: 200 to 600 mg/day, adolescents and adults)Traditional use for cough with colds and localized muscle pain
  1. 1,8-cineole capsules (enteric or gut-soluble)
    Absorption in people
    No head-to-head human data in our sources.2
    GI tolerance
    Adverse events similar to placebo in the COPD trial; occasional heartburn or rash.26
    Studied for
    COPD, asthma, acute bronchitis and sinusitis (200 mg three times daily)
  2. Eucalyptus oil for oral use
    Absorption in people
    No head-to-head human data in our sources.1
    GI tolerance
    Heartburn, abdominal pain, nausea, vomiting and diarrhoea are listed; caution with inflamed or ulcerated gut.1
    Studied for
    Traditional use for cough with colds (EU monograph: 200 to 600 mg/day, adolescents and adults)
  3. Steam inhalation, chest rubs and bath additives
    Absorption in people
    Inhaled or applied to skin.1
    GI tolerance
    Contact eczema on skin; keep eyes out of the steam and avoid burns from hot water; not on broken or irritated skin.1
    Studied for
    Traditional use for cough with colds and localized muscle pain
Every cell holds data from a cited page; citation numbers link to the page that holds them.Scroll the table for every column

What the human research says

Human trials only, one row per outcome. The form line shows what each trial actually tested. Grades follow our evidence-grading policy.

Trial map

5 graded outcomes, largest study first

All 5 graded outcomes found an improvement. The largest, a 2012 randomized trial of 247 people on lung function, asthma symptoms and quality of life (combined), found an improvement.

1Lung function, asthma symptoms and quality of life (combined)

Improved · Grade C · RCT, 247 people, 2012

Patients with confirmed asthma (multicentre)

Dose, result and source
Every graded outcome on this page, largest study first
OutcomeFoundPeopleStudyWho was studied
Lung function, asthma symptoms and quality of life (combined)Improved247Grade C · RCT, 2012Patients with confirmed asthma (multicentre)
COPD exacerbations (frequency, duration, severity)Improved242Grade B · RCT, 2009Patients with stable COPD on standard medication (multicentre)
Acute bronchitis symptom scoreImproved242Grade C · RCT, 2013Patients with acute bronchitis (multicentre)
Acute non-purulent rhinosinusitis symptom scoreImproved152Grade C · RCT, 2004Patients with acute non-purulent rhinosinusitis
Oral steroid reduction in steroid-dependent asthmaImproved32Grade D · RCT, 2003Patients with severe, steroid-dependent bronchial asthma
Each circle is one graded outcome on this page, numbered from the largest study down, and placed by how many people it studied (log scale). It shows who was studied and what was found, not advice about your dose.

Every graded row

5 rows

Showing 5 of 5 outcomes. Human trials only.

Grade BCOPD exacerbations (frequency, duration, severity)COPDImprovedRCT
n 242 · 2009

Improved Exacerbations were significantly less frequent, shorter and less severe than on placebo. Lung function, breathlessness and quality of life also improved; adverse events were similar in both groups.

Design
RCT, n = 242, 2009
Population
Patients with stable COPD on standard medication (multicentre)
Form
1,8-cineole capsules as add-on therapy
Dose
200 mg three times daily
Duration
6 months (winter)
Source
Reference 2 · PubMed 19624838 (opens PubMed)
Grade CLung function, asthma symptoms and quality of life (combined)AsthmaImprovedRCT
n 247 · 2012

Improved The combined outcome favoured cineole (p = .0027); individual measures were each only modestly significant (FEV1 p = .0398, symptoms p = .0325, quality of life p = .0475).

Design
RCT, n = 247, 2012
Population
Patients with confirmed asthma (multicentre)
Form
1,8-cineole capsules as add-on therapy
Dose
200 mg three times daily
Duration
6 months
Source
Reference 3 · PubMed 22978309 (opens PubMed)
Grade CAcute bronchitis symptom scoreAcute bronchitisImprovedRCT
n 242 · 2013

Improved After 4 days the bronchitis sum score improved more than on placebo (p = 0.0383), with fewer coughing fits (p = 0.0001).

Design
RCT, n = 242, 2013
Population
Patients with acute bronchitis (multicentre)
Form
1,8-cineole capsules
Dose
200 mg three times daily
Duration
10 days
Source
Reference 4 · PubMed 24261680 (opens PubMed)
Grade CAcute non-purulent rhinosinusitis symptom scoreSinusitisImprovedRCT
n 152 · 2004

Improved Mean symptom score fell from 15.6 to 3.0 on cineole vs 9.2 on placebo by day 7. Two patients had possibly related heartburn or rash.

Design
RCT, n = 152, 2004
Population
Patients with acute non-purulent rhinosinusitis
Form
1,8-cineole capsules
Dose
Two 100 mg capsules three times daily (600 mg/day)
Duration
7 days
Source
Reference 6 · PubMed 15064633 (opens PubMed)
Grade DOral steroid reduction in steroid-dependent asthmaAsthmaImprovedRCT
n 32 · 2003

Improved Prednisolone could be cut by 36% on cineole vs 7% on placebo (P = 0.006); 12 of 16 vs 4 of 16 patients reduced their oral steroid.

Design
RCT, n = 32, 2003
Population
Patients with severe, steroid-dependent bronchial asthma
Form
1,8-cineole in small gut-soluble capsules
Dose
200 mg three times daily
Duration
12 weeks
Source
Reference 5 · PubMed 12645832 (opens PubMed)

Common cold: timing study without a placebo

1 note

Human data that cannot be graded as an outcome here.

Earlier start, milder cold
In an open-label, non-randomized study, 329 adults who caught a cold took 200 mg cineole three times daily for up to 15 days. Those who started within 12 hours had a 38% lower symptom burden and recovered in 8.9 days versus 10.7 days when started after 24 hours; 4.3% had side effects possibly related to cineole. With no placebo group, this compares start times, not cineole against nothing.13

What the numbers add up to

Each point is worked out from the data and the sources numbered on this page, with the arithmetic shown under it. It adds no new data and is not medical advice.

Positive trials, one research group

All five cineole trials here list U. Dethlefsen of the MKL Institute of Clinical Research, Aachen, as a co-author, and two state Cassella-med funding. Independent replication would make the case much stronger.23456

How we got this: Author lists and funding statements of the cited trials

Studied doses

Doses used in research, shown against the official limits. They describe the studies, not a recommendation for you.

Studied doses in research, not advice. These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.

Doses studied in human trials

Doses studied in human trials ranged from 600 mg of 1,8-cineole a day (200 mg three times daily) for 7 to 10 days in acute sinus and bronchial infections to the same daily amount for 6 months as add-on therapy in COPD and asthma.2346

Interactions and safety

Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.

Interactions

0 agents

None found in our sources.

Check with what you take

Kept on this device only

Add what you take. We list every interaction our evidence profiles cite between Eucalyptus Oil and your picks, and between your picks.

Most cited:

Add a supplement or medicine you take to check it against Eucalyptus Oil.

Starting from one medicine? The interaction checker rates how serious each pair is, on a curated list of 19 entries for 11 medicines. This cabinet has no severity rating: it lists every interaction row our supplement pages cite.

Not medical advice, and no dosing advice. An empty result means no row we cite names that pair, by name or through a drug class we can link the medicine to, not that a combination is safe. Where our sources name only a group of medicines we cannot match, the cabinet says so. Ask your pharmacist before you combine supplements and medicines.

Who should be careful

7 groups
Infants and young children
Contraindicated under 24 months because 1,8-cineole products can trigger laryngospasm. Oral use under 12 and inhalation under 3 have not been established.1
Accidental swallowing by children
Keep the oil out of children's reach. In 109 young children admitted to a Melbourne hospital after swallowing eucalyptus oil, 28% had a depressed conscious state; the authors warn that 2 to 3 ml of pure oil can cause drowsiness and 5 ml or more significant loss of consciousness. All recovered. In a Victorian survey, 74% of young children who swallowed or may have swallowed it reached it through a home vaporiser, most often at ground level. Seizures have followed oil drops given by mouth in water or milk.7108
Children with seizures
Contraindicated in children with a history of seizures, febrile or not. Eucalyptus oil has triggered first seizures and breakthrough seizures in children with epilepsy, after swallowing, inhalation or skin use.189
Allergy
Contraindicated with hypersensitivity to eucalyptus oil or 1,8-cineole; severe systemic allergic reactions have been reported.1
Stomach or bowel inflammation
Use with caution in inflamed or ulcerated conditions of the gastrointestinal tract.1
Pregnancy and breastfeeding
Safety has not been established, and the EU monograph does not recommend use during pregnancy or breastfeeding. LactMed has no entry for eucalyptus oil or cineole (its 'oil of lemon eucalyptus' entry covers a different insect-repellent product).1
Worsening breathing
See a doctor if shortness of breath, fever or purulent sputum appears, or if cough lasts longer than a week.1
Talk to your pharmacist or clinician before starting a supplement, especially if you take prescription medicines.

Safety

5 notes

Mostly mild stomach effects in adults; real hazards for small children and in overdose.

By mouth
Heartburn, abdominal pain, nausea, vomiting and diarrhoea are listed side effects.1
Overdose
Doses above those recommended can cause vomiting, breathing problems, CNS depression, loss of consciousness, convulsions, ataxia and constricted pupils. In young children, swallowing a few millilitres of pure oil has caused drowsiness and, at 5 ml or more, significant loss of consciousness.17
Seizures
In a prospective series of 17 children (median age 3.75 years) who had generalized seizures after eucalyptus oil drops by mouth, seizures began a median 20 minutes after exposure and none recurred over 6 to 9 months. A review of 110 published cases (49 children) found inhalation the most common route; adults were less likely than children to have prolonged or repeated seizures needing intensive care.89
Skin
Contact eczema can occur; do not apply to broken or irritated skin, and wash hands to avoid eye irritation.1
Interactions
The EU monograph reports no known drug interactions, and no interaction studies or case reports turned up in our 2026 PubMed search; LiverTox has no eucalyptus entry.1

How to read the label

What to check on the Supplement Facts panel.

How to read the label

3 checks
Cineole vs whole oil

The trials used isolated 1,8-cineole at 200 mg per dose. A eucalyptus oil product is a different preparation from the cineole capsules that were tested.12

Label dose vs clinical dose

Trials used 600 mg of cineole a day; the EU monograph's oral range for eucalyptus oil is 200 to 600 mg a day for adolescents and adults.12

Keep it away from small children

Products are contraindicated under 2 years, including chest rubs and inhalations.1

Frequently asked questions

Short answers to common questions; the numbers link to the sources below.

Common questions

7 answers
Does cineole help COPD?

In one 242-patient trial, 200 mg three times daily as add-on therapy for 6 winter months reduced the frequency, length and severity of flare-ups. The trial was company-funded and has not been independently repeated.2

Does it help a chest cold or sinus infection?

Trials of 7 to 10 days found faster symptom relief in acute bronchitis and acute non-purulent sinusitis, both from the same research group.46

Is eucalyptus oil safe for babies?

No. EU regulators contraindicate it under 24 months because cineole products can cause laryngospasm, and in children with a history of seizures.1

What happens if someone swallows too much?

Overdose can cause vomiting, breathing problems, CNS depression, convulsions and loss of consciousness. Young children are most at risk: 2 to 3 ml of pure oil can cause drowsiness, and 5 ml or more significant loss of consciousness, so swallowing it needs urgent medical advice.17

Can eucalyptus oil cause seizures?

Yes, rarely. Seizures have followed swallowing, inhaling or rubbing on eucalyptus oil. In 17 children who had seizures after oral drops, fits began a median 20 minutes later; a review of 110 cases found children more likely than adults to need intensive care. The EU monograph rules it out for children with a history of seizures.891

Is it safe to use a eucalyptus vaporiser around young children?

Use care. In a Victorian survey, 74% of young children who swallowed or may have swallowed eucalyptus oil got it from a home vaporiser, often left at ground level, and EU rules contraindicate inhalation products under 2 years.101

Is eucalyptus oil the same as cineole?

No. 1,8-cineole (eucalyptol) is the main constituent of eucalyptus oil. The trials tested isolated cineole capsules, not whole oil.12

Sources

13 sources: trial abstracts, NIH fact sheets and reference databases. Numbers in the text link here.

Sources cited on this page

13 sources
  1. 1European Union herbal monograph on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum (Revision 1, EMA/HMPC/320292/2023)Guideline European Medicines Agency (HMPC), 2024 · ema.europa.eu
  2. 2Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial.RCT Respir Res, 2009 · PMID 19624838
  3. 3Patients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial.RCT J Asthma, 2012 · PMID 22978309
  4. 4Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial.RCT Cough, 2013 · PMID 24261680
  5. 5Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial.RCT Respir Med, 2003 · PMID 12645832
  6. 6Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial.RCT Laryngoscope, 2004 · PMID 15064633
  7. 7Clinical effects and management of eucalyptus oil ingestion in infants and young children.Observational Med J Aust, 1995 · PMID 7651249
  8. 8Eucalyptus Oil-Induced Seizures in Children: A Single-Center Prospective Study.Observational Cureus, 2021 · PMID 33927923
  9. 9Clinico-laboratory characteristics and outcome of patients with eucalyptus oil-induced/provoked seizures: A case series and systematic review of the published patients.Systematic review Trop Doct, 2021 · PMID 34282989
  10. 10Eucalyptus oil poisoning among young children: mechanisms of access and the potential for prevention.Observational Aust N Z J Public Health, 1997 · PMID 9270157
  11. 11Efficacy and safety of mucolytic agents in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis.Meta-analysis BMC Pulm Med, 2026 · PMID 41688985
  12. 12Effects of Essential Oils in the Treatment of Acute Rhinosinusitis: A Systematic Review.Systematic review Laryngoscope Investig Otolaryngol, 2025 · PMID 40575453
  13. 13The impact of cineole treatment timing on common cold duration and symptoms: Non-randomized exploratory clinical trial.Open-label trial PLoS One, 2024 · PMID 38236839

What changed

Every dated change to this page: what changed, who made it and why.

Change log

3 entries
Dated changes to this page
DateChangeWho and why
summary, key facts, evidence notes, research notes, who should avoid, safety, FAQ, questions, relatedAdded child-poisoning data: a 2021 prospective series of 17 children with seizures after oral eucalyptus oil drops, a 2021 review of 110 published seizure cases (49 children) and a 1997 Victorian survey showing most young children reached the oil through home vaporisers; these now feed the summary, key facts, safety notes and two new FAQ items. Added a 2026 network meta-analysis of COPD mucolytics (cineole ranked best for fewer flare-ups and side effects) and a 2025 rhinosinusitis systematic review to the evidence notes, and a 2024 open-label common-cold timing study as an ungraded research note (no placebo group). Pregnancy note now records that LactMed has no eucalyptus oil entry. Interactions re-checked: none in the EU monograph or PubMed; LiverTox has no entry. Not added as rows: a 2025 trial of a combined eucalyptol-limonene-pinene capsule (not cineole alone).Writer: Kymata Health EditorialTrigger: A–Z audit against docs/supplements/AUDIT-STANDARD.md
allInitial editorial evidence review (first draft). Every PMID checked against NCBI E-utilities esummary (title and year) and each cited abstract read; numbers taken from the abstracts. No retractions or errata linked to the cited PMIDs. Funding: the COPD (2009) and acute bronchitis (2013) trials state a grant from Cassella-med, Cologne; the other three trials do not state funding in their abstracts and share the co-author U. Dethlefsen. Safety, interaction and pregnancy text come only from the EMA herbal monograph (Revision 1, adopted 20 November 2024; no interactions reported). No product links.Writer: Kymata Health EditorialTrigger: new page
evidence and safetyAdversarial review: added child ingestion toxicity from a 109-child hospital series (PMID 7651249) to the summary, key facts, who-should-avoid, safety and FAQ; named U. Dethlefsen's affiliation (MKL Institute of Clinical Research).Writer: Kymata Health EditorialTrigger: adversarial review

Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.

Educational only. Not medical advice. Some links earn us a commission: kymatahealth.com/affiliate-disclosure.